[Clinical experience with a combination of a new beta-blocking agent, LB 46, and quinidine in the treatment of chronic atrial fibrillation].
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001281:Atrial Fibrillation / Q000188:drug therapy*; D002908:Chronic Disease; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011802:Quinidine / Q000627:therapeutic use*; D013565:Sympatholytics / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D004338:Drug Combinations; D013565:Sympatholytics; D011802:Quinidine
Associazione di un nuovo beta-bloccante, LB 46, con idrochinidina per il trattamento della fibrillazione atriale cronica.